Predictive factors for efficacy of interferon therapy in chronic hepatitis type C

It has recently become possible to quantify HCV-RNA in serum and to analyze the HCV-RNA genotype. In this study, we investigated the relationship among the response to interferon therapy, the HCV-RNA concentration, genotype and histological findings of the liver.

Sixty-three patients with chronic hepatitis type C received interferon alfa therapy for 24 weeks. The HCV-RNA concentration in serum was measured semiquantitatively with reverse transcript semi-nested polymerase chain reaction and classified as negative to +3. HCV-RNA genotype was analyzed using a mixture of four type specific primers.

HCV-RNA concentration was significantly higher in patients with genotype II and CAH2B than genotype III, CPH and CAH2A (p < 0.05). At 24 weeks after the end of interferon therapy, HCV-RNA in serum disappeared in 24 of 63 patients (38%). Strong resistance to the therapy was noted in patients with both genotype II and a high concentration of HCV-RNA in serum (the efficacy was only 7%). Therapy efficacy decreased with the severity of liver histological findings, reaching only 20% in those with CAH2B.

Both the concentration and genotype of HCV-RNA seem to be important factors in determining the efficacy of interferon therapy.